MICROENCAPSULATED MEASLES VIRUS VACCINE

描述：（改编自申请人的摘要）长期 本提案的目的是开发商业化的亚单位疫苗 抗MV感染。 由于准备表面的成本很高 抗原，用于实现增强的免疫应答的手段是 这是一个重要的目标，也是这项建议的重点。 生物相容 和由DL-丙交酯的共聚物组成的可生物降解的微球， 和乙交酯（聚DL-丙交酯-共-丙交酯）将用于 将MV抗原掺入小的球形颗粒（1 - 10 μ m）中。 含有病毒抗原的微球将用于皮下， 鼻内和口服免疫小鼠，免疫应答将 被评价。 另一组小鼠将类似地用 在溶液中灭活的病毒用于比较。 如果显著增强 使用微囊化MV观察到保护性免疫应答 抗原，随后将进行更详细的研究。 研究 也将进行了解保护机制 （细胞/抗体介导的）和这种应答的持续时间。 最终将使用微胶囊麻疹病毒疫苗 用于麻疹感染免疫预防的临床田间试验。

DESCRIPTION: (Adapted from the applicant's abstract) The long term objective of this proposal is to develop a commercial subunit vaccine against MV infection. Because of the high cost of preparing the surface antigens, a means for achieving an enhanced immune response is an important objective and is the focus of this proposal. Biocompatible and biodegradable microspheres consisting of a copolymer of DL-lactide and glycolide (poly DL-lactide-co- lactide) will be utilized to incorporate MV antigens into small spherical particles (l-l0um). Microspheres containing viral antigens will be used for subcutaneous, intranasal and oral immunization of mice, and the immune response will be evaluated. Another group of mice will be similarly immunized with inactivated virus in solution for comparison. If significant enhancement in the protective immune response is observed using microencapsulated MV antigens, more detailed studies will be pursued subsequently. Studies will also be conducted to understand the mechanism of protection (cellular/antibody mediated) and the duration of such response. Ultimately, a microencapsulated measles virus vaccine will be utilized in clinical field trials for immunoprophylaxis against measles infection.